Revision of the Outcome of the Meeting Dt 13.08.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemo Organic's Board approved unaudited standalone results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations crashed to just ₹0.19 lakh from ₹241.43 lakh in the same quarter last year, and the company swung to a loss of ₹8.57 lakh versus a profit of ₹37.34 lakh earlier. Total income for the quarter stood at only ₹0.38 lakh versus ₹250.38 lakh year-on-year, signalling a near-complete collapse in business activity. The statutory auditor (MAAK & Associates) issued a qualified review report, flagging that no balance confirmations were provided for trade receivables and trade payables. The Board also approved the FY24-25 Director's Report, fixed the 33rd AGM for September 29, 2025 via video conferencing, and noted that a ₹11,800 penalty (inclusive of GST) levied by BSE under SEBI LODR Regulation 29(2)/29(3) had already been paid on June 18, 2025.
Sharp revenue collapse and a return to losses, combined with an auditor qualification on receivables/payables, are negative signals for shareholders and could weigh on the stock. The BSE penalty points to prior compliance lapses, adding to governance concerns for this small-cap company.